LRMR - NASDAQ

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.20

-3.0%

HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$273.97M

EPS-2.2700

P/E Ratio-1.41

Earnings Date08/06/2026

lrmr

Sales/Maturities of Investments

Last Annual Value

184.00M

3-Year CAGR

63%

5-Year CAGR

184%

10-Year CAGR

-1%

Adjust for Inflation

Larimar Therapeutics, Inc. Competitors Analysis of Sales/Maturities of Investments

LRMR · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Larimar Therapeutics, Inc. NASDAQ:LRMR	184.00M	10.9%	41.2%	-0.2%
Alector, Inc. NASDAQ:ALEC	468.52M	-10.6%	9.5%	N/A
Editas Medicine, Inc. NASDAQ:EDIT	139.01M	-18.8%	-17.4%	N/A
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	5.00M	-5.9%	N/A	N/A
Lyell Immunopharma, Inc. NASDAQ:LYEL	374.68M	-17.3%	-9.5%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	56.70M	-19.0%	N/A	N/A
Voyager Therapeutics, Inc. NASDAQ:VYGR	261.97M	45.2%	26.0%	4.7%
Replimune Group, Inc. NASDAQ:REPL	386.48M	-4.5%	13.4%	N/A
Kyverna Therapeutics, Inc. NASDAQ:KYTX	398.81M	104.4%	N/A	N/A
Korro Bio, Inc. NASDAQ:KRRO	70.70M	55.0%	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock NASDAQ:LXEO	105.53M	N/A	N/A	N/A

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.2014, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.2014

Related Guides

Blog Categories

Continue your LRMR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.